1163 related articles for article (PubMed ID: 16397519)
21. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events.
Papademetriou V
Am Heart J; 2009 Jun; 157(6 Suppl):S24-30. PubMed ID: 19450721
[TBL] [Abstract][Full Text] [Related]
23. Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy.
Cohn JN; Goldman JM
Am J Hypertens; 2008 Mar; 21(3):248-56. PubMed ID: 18219303
[TBL] [Abstract][Full Text] [Related]
24. [ACE inhibitors in the treatment of hypertension in elderly patients].
Evéquoz D; Reichenstein T; Waeber B; Nussberger J; Brunner HR
Schweiz Rundsch Med Prax; 1991 Jun; 80(25):701-6. PubMed ID: 1857901
[TBL] [Abstract][Full Text] [Related]
25. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
Abassi Z; Armaly Z; Nakhoul F; Hoffman A
Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
[TBL] [Abstract][Full Text] [Related]
26. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
Bommer WJ
Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin receptor antagonists and ACE inhibitors.
Howes LG; Christie N
Aust Fam Physician; 1998 Oct; 27(10):914-7, 919-21. PubMed ID: 9798290
[TBL] [Abstract][Full Text] [Related]
28. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
Verdecchia P; Gentile G; Angeli F; Reboldi G
Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
[TBL] [Abstract][Full Text] [Related]
29. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
Ferri C; Croce G; Desideri G
Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
[TBL] [Abstract][Full Text] [Related]
30. Inhibiting the renin-angiotensin system: why and in which patients.
Berra K; Miller NH
J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
[TBL] [Abstract][Full Text] [Related]
31. [Inhibition of the renin-angiotensin system: ACE inhibitors and angiotensin II receptor blockers].
Pichler M; Klein W; Huber K; Pachinger O
Wien Med Wochenschr; 1996; 146(11):228-31. PubMed ID: 8928520
[TBL] [Abstract][Full Text] [Related]
32. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
33. Hypertension. Update on use of angiotensin II receptor blockers.
Jacobson EJ
Geriatrics; 2001 Feb; 56(2):20-1, 25-8. PubMed ID: 11219021
[TBL] [Abstract][Full Text] [Related]
34. Angiotensin II type 1 receptor blockade: a novel therapeutic concept.
Johnston CI
Blood Press Suppl; 2000; 1():9-13. PubMed ID: 11059629
[TBL] [Abstract][Full Text] [Related]
35. Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Lyle PA; Tershakovec AM; Devereux RB; Oparil S; Dahlöf B; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Wedel H
Expert Opin Emerg Drugs; 2005 Nov; 10(4):729-45. PubMed ID: 16262560
[TBL] [Abstract][Full Text] [Related]
36. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension.
Motwani JG
J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):72-8. PubMed ID: 12228846
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin II receptor antagonists role in arterial hypertension.
Hernández-Hernández R; Sosa-Canache B; Velasco M; Armas-Hernández MJ; Armas-Padilla MC; Cammarata R
J Hum Hypertens; 2002 Mar; 16 Suppl 1():S93-9. PubMed ID: 11986904
[TBL] [Abstract][Full Text] [Related]
38. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD;
Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449
[TBL] [Abstract][Full Text] [Related]
39. [Antihypertensive treatment for patients with hypertension and diabetes type II--current clinical research].
Rajzer M; Kawecka-Jaszcz K; Wojciechowska W
Przegl Lek; 2003; 60(2):111-5. PubMed ID: 12939858
[TBL] [Abstract][Full Text] [Related]
40. Renin-angiotensin system modulation: the weight of evidence.
Brown B; Hall AS
Am J Hypertens; 2005 Sep; 18(9 Pt 2):127S-133S. PubMed ID: 16125049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
